Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Theophylline in the Treatment of Bronchiectasis

This study has been completed.
Information provided by (Responsible Party):
Xugang, The First Affiliated Hospital of Guangzhou Medical University Identifier:
First received: September 11, 2012
Last updated: March 10, 2015
Last verified: March 2015
Theophylline was well recommended in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. However, there is no supporting evidence for their efficacy in the treatment of bronchiectasis. Our hypothesis is that theophylline will play a role in bronchiectasis. Our purpose is to examine the efficacy and safety of 24 weeks treatment with theophylline in subjects with non-cystic fibrosis bronchiectasis.

Condition Intervention Phase
Drug: Theophylline
Drug: Placebo(for Theophylline)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Efficacy and Safety of Theophylline in the Treatment of Non-Cystic Fibrosis(NCF) Bronchiectasis

Resource links provided by NLM:

Further study details as provided by The First Affiliated Hospital of Guangzhou Medical University:

Primary Outcome Measures:
  • Scores of the St.George's Respiratory Questionnaire [ Time Frame: At 24 weeks ]

Secondary Outcome Measures:
  • The Number of Exacerbations [ Time Frame: At 24 weeks ]
  • Scores of The Leicester Cough Questionnaire [ Time Frame: At 24 weeks ]
  • 24 Hour Sputum Volume [ Time Frame: Every day for 24 weeks ]
  • Activity of histone deacetylase(HDAC) [ Time Frame: At 24 weeks ]
    HDACs are extracted from cells in blood.

  • Activity of histone acetyltransferase(HAT) [ Time Frame: At 24 weeks ]
    HATs are extracted from cells in blood.

  • Lung function [ Time Frame: At 24 weeks ]
    Lung function as measured by FEV1, FVC, FEV1%, FEV1/FVC, FEF25-75 values following American Thoracic Society(ATS) guidelines

  • Induced sputum culture [ Time Frame: At 24 weeks ]
  • Induced Sputum Cytology Count [ Time Frame: At 24 weeks ]
  • Interleukin-6(IL-6) [ Time Frame: At 24 weeks ]
    Test IL-6 both in blood and sputum.

  • C-Reactive Protein [ Time Frame: At 24 weeks ]
  • To evaluate change in patients' Clinical Data [ Time Frame: Every day for 24 weeks ]
    Clinical Data contain dyspnea, cough, wheezes, hemoptysis, sputum characteristics, sputum volume.

  • Number of participants with adverse events [ Time Frame: Up to 24 weeks ]
    Adverse events may contain symptoms such as nausea, sickness, headache, insomnia, palpitation, arrhythmia and so on. Record the symptoms and times of the patients.

  • Plasma Concentration of Theophylline [ Time Frame: At 24 weeks ]
    Venous blood was taken for plasma theophylline at the end of the treatment period. (At the very time of 2 hours after patients taken the pills)

  • IL-8 [ Time Frame: At 24 weeks ]
    Test IL-8 both in blood and sputum.

  • IL-10 [ Time Frame: At 24 weeks ]
    Test IL-10 both in blood and sputum.

  • Human Tumor Necrosis Factor α(TNF-α) [ Time Frame: At 24 weeks ]
    Test TNF-α both in blood and sputum.

  • 8-Isoprostane [ Time Frame: At 24 weeks ]
  • Blood routine examination [ Time Frame: At 24 weeks ]

Enrollment: 100
Study Start Date: November 2012
Study Completion Date: September 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Theophylline
Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks
Drug: Theophylline
Theophylline 0.1 bid
Other Name: Theophylline Sustained-Release Tablet.
Placebo Comparator: placebo
Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks
Drug: Placebo(for Theophylline)
Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)

Detailed Description:
For the reasons of lack of sufficient clinical trial evidences, there are no standard therapy recommendations for bronchiectasis. Currently the treatments for bronchiectasis are mostly based on experience gained from the treatment of COPD and cystic fibrosis(CF). The aims of treatment for bronchiectasis are to improve the health-related quality of life, to slow down the decrease of lung function, to reduce the exacerbation frequence and the mortality. The mechanism of treatment are including: treating the underlying disease; improving drainage of sputum; anti-infection; anti-inflammation; treating airway obstruction. A review written by Peter J. Barnes describes that as a bronchodilator in COPD, theophylline may relax human airways smooth muscle, have an anti-inflammation rols, and have an additional effect on mucociliary clearance. Besides, theophylline can improve the activity of histone deacetylase, which will reverse the resistant of corticosteroids. We hypothesis that theophylline will have the same effect in subjects with NCF-bronchiectasis as in subjects with COPD. Our trial may give an evidence of using theophylline in treatment of bronchiectasis.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients between 18-70 years old with non-CF bronchiectasis ,free from acute exacerbations for at least 3 months.Stable phase of the disease.

Exclusion Criteria:

  • Patients with a cigarette smoking history of more than 10 packs-year. Patients with COPD. Patients with traction bronchiectasis due to advanced fibrosis. Patients with known intolerance for theophylline. Patients with asthma. Patients with other disease disturbing outcomes of the trials. Patients without consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01684683

China, Guangdong
State Key Laboratory of Respiratory Research Institute.
Guangzhou City, Guangdong, China, 510000
Sponsors and Collaborators
The First Affiliated Hospital of Guangzhou Medical University
Study Director: Chen Rongchang, Professor institute vice director
Study Director: Zhong Nanshan, Professor institute director
  More Information

Responsible Party: Xugang, Doctor of Medicine, The First Affiliated Hospital of Guangzhou Medical University Identifier: NCT01684683     History of Changes
Other Study ID Numbers: theophylline in NCFB
Study First Received: September 11, 2012
Last Updated: March 10, 2015

Keywords provided by The First Affiliated Hospital of Guangzhou Medical University:
Therapeutic Uses
Random placebo study

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents processed this record on April 25, 2017